|
|
viii | |
Foreword |
|
ix | |
|
1 Introduction to the WHO Reporting System for Lung Cytopathology |
|
|
1 | (12) |
|
|
2 | (4) |
|
The role of lung cytopathology |
|
|
6 | (2) |
|
Diagnostic categories and report structure |
|
|
8 | (3) |
|
Risk of malignancy and management recommendations |
|
|
11 | (2) |
|
2 Lung cytopathology techniques |
|
|
13 | (26) |
|
Sampling methods FNAB techniques and specimen management |
|
|
14 | (2) |
|
Bronchial wash and bronchial brush techniques and specimen management |
|
|
16 | (2) |
|
Bronchoalveolar lavage techniques and specimen management |
|
|
18 | (2) |
|
Sputum sampling techniques and specimen management |
|
|
20 | (2) |
|
|
22 | (2) |
|
|
24 | (2) |
|
Ancillary testing Introduction: The role of ancillary testing |
|
|
26 | (1) |
|
|
27 | (4) |
|
|
31 | (3) |
|
|
34 | (5) |
|
3 Diagnostic category: Insufficient/lnadequate/Non-diagnostic |
|
|
39 | (8) |
|
|
40 | (1) |
|
|
40 | (1) |
|
Discussion and background |
|
|
41 | (3) |
|
Risk of malignancy and management recommendations |
|
|
44 | (1) |
|
|
45 | (2) |
|
4 Diagnostic category: Benign |
|
|
47 | (38) |
|
|
48 | (1) |
|
|
48 | (1) |
|
Discussion and background |
|
|
49 | (1) |
|
Risk of malignancy and management recommendations |
|
|
50 | (1) |
|
Inflammatory processes Acute inflammation and suppuration |
|
|
51 | (2) |
|
Histiocytic, lymphocytic, and eosinophilic inflammatory patterns |
|
|
53 | (5) |
|
|
58 | (3) |
|
Inflammatory and reactive changes in glandular cells and squamous cells |
|
|
61 | (5) |
|
Benign neoplastic lesions Pulmonary hamartoma |
|
|
66 | (2) |
|
|
68 | (3) |
|
Solitary tracheobronchial papilloma |
|
|
71 | (1) |
|
|
72 | (1) |
|
|
73 | (2) |
|
|
75 | (3) |
|
|
78 | (1) |
|
|
79 | (2) |
|
Ectopic thyroid and parathyroid tissues |
|
|
81 | (2) |
|
|
83 | (2) |
|
5 Diagnostic category: Atypical |
|
|
85 | (10) |
|
|
86 | (1) |
|
|
86 | (1) |
|
Discussion and background |
|
|
87 | (3) |
|
Risk of malignancy and management recommendations |
|
|
90 | (1) |
|
|
91 | (4) |
|
6 Diagnostic category: Suspicious for malignancy |
|
|
95 | (8) |
|
|
96 | (1) |
|
|
96 | (1) |
|
Discussion and background |
|
|
97 | (2) |
|
Risk of malignancy and management recommendations |
|
|
99 | (1) |
|
|
100 | (3) |
|
7 Diagnostic category: Malignant |
|
|
103 | (74) |
|
|
104 | (1) |
|
|
104 | (1) |
|
Discussion and background |
|
|
105 | (3) |
|
Risk of malignancy and management recommendations |
|
|
108 | (1) |
|
Specific malignant lesions Non-small cell carcinomas Adenocarcinoma of the lung |
|
|
109 | (5) |
|
|
114 | (4) |
|
Non-small cell carcinoma NOS |
|
|
118 | (2) |
|
Other specific carcinomas Salivary gland-type carcinomas |
|
|
120 | (3) |
|
|
123 | (3) |
|
|
126 | (2) |
|
|
128 | (1) |
|
|
129 | (2) |
|
|
131 | (2) |
|
Thoracic SMARCA4-deficient undifferentiated tumour |
|
|
133 | (2) |
|
Neuroendocrine neoplasms Neuroendocrine tumours Carcinoid/neuroendocrine tumours of the lung |
|
|
135 | (4) |
|
Neuroendocrine carcinomas Small cell lung carcinoma |
|
|
139 | (3) |
|
Large cell neuroendocrine carcinoma |
|
|
142 | (2) |
|
Lymphoproliferative diseases Lymphomas |
|
|
144 | (3) |
|
Pulmonary Langerhans cell histiocytosis |
|
|
147 | (1) |
|
|
148 | (2) |
|
Other malignancies Spindle cell tumours |
|
|
150 | (4) |
|
|
154 | (2) |
|
Diffuse pleural mesothelioma |
|
|
156 | (7) |
|
Primary germ cell tumours of the mediastinum |
|
|
163 | (5) |
|
Primary angiosarcoma of the lung |
|
|
168 | (2) |
|
Pulmonary and thoracic metastases |
|
|
170 | (3) |
|
|
173 | (4) |
|
8 Management recommendations for each diagnostic category |
|
|
177 | (12) |
|
|
178 | (1) |
|
Insufficient/lnadequate/Non-diagnostic |
|
|
179 | (2) |
|
|
181 | (1) |
|
|
182 | (1) |
|
Suspicious for malignancy |
|
|
183 | (1) |
|
|
184 | (1) |
|
|
185 | (2) |
|
|
187 | (2) |
Sources |
|
189 | (4) |
References |
|
193 | (16) |
Subject Index |
|
209 | |